查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1818079

2032 年生技藥品和生物相似藥市場預測：按產品類型、治療領域、製造商、分銷管道、最終用戶和地區進行的全球分析

Biologics & Biosimilars Market Forecasts to 2032 - Global Analysis By Product Type, Therapeutic Area, Manufacturing Source, Distribution Channel, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球生技藥品和生物相似藥市場預計在 2025 年達到 5,382 億美元，到 2032 年將達到 1,2198.6 億美元，預測期內複合年成長率為 12.4%。

生技藥品是指利用活細胞或生物體製造的創新療法，例如單株抗體、蛋白質和疫苗，用於治療慢性和嚴重。生物相似藥是在生技藥品專利保護到期後研發的，其安全性、有效性和品質與生物製劑相似，從而確保相同的治療效果。這些經濟高效的選擇擴大了患者獲得重要療法的管道。生技藥品和生物相似藥協同作用，透過推進醫療解決方案、降低治療成本和改善整體臨床療效，提升醫療保健水準。

慢性病增多

在全球範圍內，癌症、糖尿病和自體免疫疾病等慢性疾病的發生率不斷上升，推動了對生技藥品和生物相似藥的需求。醫療保健系統優先考慮能夠提高療效、減少副作用的長期治療方案。具有標靶作用機制的生技藥品正成為疾病管理策略的核心。隨著患者群體老化和診斷能力的提高，對生技藥品的需求持續成長。生物相似藥作為一種經濟高效的替代方案，正日益受到青睞，尤其是在醫療保健預算緊張的市場。這種日益成長的需求正在加速整個生物製藥產業的創新和投資。

開發和製造成本高

生技藥品和生物相似藥的開發涉及從細胞株工程到純化和驗證的複雜流程。嚴格的監管要求和漫長的臨床試驗時間進一步加劇了高成本。生產設施必須滿足嚴格的品質標準，並且通常需要專業的基礎設施和熟練的人員。低溫運輸物流和污染控制的需求進一步增加了營運成本。規模較小的公司面臨進入壁壘，限制了競爭，並減緩了市場擴張。因此，定價仍然是一個挑戰，尤其是在新興國家。

研發和製造領域的技術進步

先進的分析技術和人工智慧驅動的建模技術正在加速藥物研發並縮短開發週期。細胞培養基和表達系統的創新正在提高產量和產品一致性。自動化數位雙胞胎正被用於最佳化設施營運並減少人為錯誤。這些進步正在降低成本，並實現複雜生技藥品的可擴展生產。隨著技術的成熟，提供具有競爭力的生物相似藥產品的公司得以進入市場。

激烈的競爭和價格壓力

專利到期導致多家製藥公司進入該領域，加劇了價格競爭。法規雖然不斷發展，但仍是阻礙市場進入和增加合規成本的障礙。付款人和醫療保健提供者要求降低價格，從而擠壓了整個價值鏈的利潤率。品牌忠誠度和醫生對生物相似藥的猶豫也影響了採用率。如果沒有差​​異化和策略定位，企業將在日益商品化的環境中面臨失去市場佔有率的風險。

COVID-19的影響

疫情擾亂了生技藥品和生物相似藥的臨床試驗、供應鏈和生產流程。封鎖措施以及疫苗和緊急治療資源的重新分配，推遲了與新冠疫情無關的產品上市。然而，這場危機凸顯了生技藥品在管理感染疾病和免疫反應的重要性。生物製藥公司加速數位轉型，並採用遠端監控和分散式檢測模式。各國政府和監管機構引入了靈活的框架，以維持藥物研發的連續性。疫情後的策略越來越強調生技藥品生產的韌性、敏捷性和全球協作。

生技藥品領域預計將成為預測期內最大的細分市場

由於療效卓越且適應症不斷擴展，生技藥品領域預計將在預測期內佔據最大市場佔有率。單株抗體、重組蛋白和基因療法正在獲得廣泛的臨床認可。複雜疾病的日益普及推動了對生物目標療法的需求。在可靠的臨床數據和患者接受度的支持下，監管核准正在加速。生技藥品的研發投入持續超過其他領域，鞏固了其市場領先地位。隨著生技藥品的普及，其在全球生技藥品支出中的佔有率預計將穩步上升。

生物製藥公司部門預計在預測期內以最高複合年成長率成長

在積極創新和產品線不斷拓展的推動下，生物製藥公司預計將在預測期內實現最高成長率。這些公司利用先進的平台進行生技藥品的合成、配製和遞送。戰略聯盟和許可協議使其能夠更快地進入市場並擴大地域覆蓋範圍。生物製藥公司也正在投資生物相似藥組合，以抓住專利到期後的機會。他們的敏捷性和對利基療法的專注使其在持續成長方面佔據有利地位。在個人化醫療需求日益成長的背景下，生物製藥公司在生技藥品開發方面處於主導。

比最大的地區

受醫療保健支出成長和患者人數不斷增加的推動，預計亞太地區將在預測期內佔據最大的市場佔有率。中國、印度和韓國等國家正在大力投資，以更新生技藥品基礎設施和法規。國內製造商正在擴大生產規模，以滿足國內和出口需求。政府舉措正在推動生物相似藥的推廣應用，以降低治療成本。臨床試驗活動蓬勃發展，亞太地區正逐漸成為生技藥品研究的中心。該地區的人口和經濟動態是該行業的關鍵成長引擎。

複合年成長率最高的地區

在技​​術領先地位和強勁的生物製藥投資的推動下，北美預計將在預測期內實現最高的複合年成長率。美國和加拿大正在透過產學研合作和聯邦資金推動生技藥品創新。監管機構正在簡化生物相似藥的核准途徑，鼓勵市場競爭。精準醫療和生技藥品的應用正在各個治療領域加速發展。數位健康整合和人工智慧主導的藥物開發正在提高效率和療效。

免費客製化服務

此報告的訂閱者可以選擇以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球生技藥品和生物相似藥市場（依產品類型）

  • 生技藥品
    • 單株抗體
    • 重組蛋白
    • 荷爾蒙
    • 疫苗
    • 細胞激素和干擾素
    • 融合蛋白
  • 生物相似藥
    • 單株抗體生物相似藥
    • 低分子量肝素
    • 重組荷爾蒙生物相似藥
    • 免疫調節藥物
    • 抗發炎生物相似藥

6. 全球生技藥品和生物相似藥市場（依治療領域）

  • 腫瘤學
  • 眼科
  • 自體免疫疾病
  • 心血管系統
  • 內分泌學
  • 感染疾病
  • 血液學
  • 創傷治療和再生護理

7. 全球生技藥品和生物相似藥市場（按製造商）

  • 哺乳動物細胞培養
  • 酵母表現系統
  • 細菌細胞培養
  • 基因改造模型

8. 全球生技藥品和生物相似藥市場（按分銷管道）

  • 醫院藥房
  • 專科診所
  • 零售藥局
  • 網路藥局

9. 全球生技藥品和生物相似藥市場（按最終用戶分類）

  • 醫院
  • 診斷實驗室
  • 研究所
  • 生物製藥公司
  • 其他

10. 全球生技藥品和生物相似藥市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Amgen
  • Sanofi
  • Pfizer
  • Eli Lilly
  • Novartis
  • Viatris
  • Biocon Biologics
  • AbbVie
  • Samsung Bioepis
  • Teva Pharmaceuticals
  • Celltrion
  • Fresenius Kabi
  • Roche
  • Boehringer Ingelheim
  • Merck KGaA
Product Code: SMRC31042

According to Stratistics MRC, the Global Biologics & Biosimilars Market is accounted for $538.20 billion in 2025 and is expected to reach $1219.86 billion by 2032 growing at a CAGR of 12.4% during the forecast period. Biologics are innovative therapies produced using living cells or organisms, such as monoclonal antibodies, proteins, and vaccines, that target chronic and severe diseases. Biosimilars, created after biologics lose patent protection, are close replicas in terms of safety, efficacy, and quality, ensuring similar therapeutic effects. These cost-effective options expand patient access to critical treatments. Together, biologics and biosimilars enhance healthcare by advancing medical solutions, reducing treatment costs, and improving overall clinical outcomes.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

The increasing global burden of chronic illnesses such as cancer, diabetes, and autoimmune disorders is fuelling demand for biologics and biosimilars. Healthcare systems are prioritizing long-term treatment solutions that offer improved efficacy and reduced side effects. Biologics, with their targeted mechanisms, are becoming central to disease management strategies. As patient population's age and diagnostic capabilities improve, the need for biologic therapies continues to rise. Biosimilars are gaining traction as cost-effective alternatives, especially in markets with strained healthcare budgets. This growing demand is accelerating innovation and investment across the biopharmaceutical landscape.

Restraint:

High development and manufacturing costs

Developing biologics and biosimilars involves complex processes, from cell line engineering to purification and validation. These high costs are compounded by stringent regulatory requirements and extended clinical trial timelines. Manufacturing facilities must meet rigorous quality standards, often requiring specialized infrastructure and skilled personnel. The need for cold chain logistics and contamination control further increases operational expenses. Smaller firms face barriers to entry, limiting competition and slowing market expansion. As a result, pricing remains a challenge, especially in emerging economies.

Opportunity:

Technological advancements in R&D and manufacturing

Advanced analytics and AI-driven modelling are enhancing drug discovery and reducing development timelines. Innovations in cell culture media and expression systems are improving yield and product consistency. Automation and digital twins are being adopted to optimize facility operations and reduce human error. These advancements are lowering costs and enabling scalable production of complex biologics. As technology matures, more players can enter the market with competitive biosimilar offerings.

Threat:

Intense competition and pricing pressure

Patent expirations are opening the door to multiple entrants, intensifying pricing battles. Regulatory pathways, while evolving, still pose hurdles that delay market access and increase compliance costs. Payers and healthcare providers are demanding lower prices, squeezing margins across the value chain. Brand loyalty and physician hesitancy toward biosimilars also impact adoption rates. Without differentiation and strategic positioning, companies risk losing market share in an increasingly commoditized landscape.

Covid-19 Impact

The pandemic disrupted clinical trials, supply chains, and manufacturing schedules for biologics and biosimilars. Lockdowns and resource reallocation toward vaccines and emergency treatments delayed non-COVID product launches. However, the crisis also highlighted the importance of biologics in managing infectious diseases and immune responses. Biopharma companies accelerated digital transformation, adopting remote monitoring and decentralized trial models. Governments and regulators introduced flexible frameworks to maintain continuity in drug development. Post-pandemic strategies now emphasize resilience, agility, and global collaboration in biologics manufacturing.

The biologics segment is expected to be the largest during the forecast period

The biologics segment is expected to account for the largest market share during the forecast period, its superior therapeutic outcomes and expanding indications. Monoclonal antibodies, recombinant proteins, and gene therapies are gaining widespread clinical acceptance. Increasing prevalence of complex diseases is driving demand for targeted biologic treatments. Regulatory approvals are accelerating, supported by robust clinical data and patient advocacy. Investment in biologics R&D continues to outpace other segments, reinforcing its market leadership. As biologics become more accessible, their share in global pharmaceutical spending is expected to rise steadily.

The biopharma companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biopharma companies segment is predicted to witness the highest growth rate, driven by aggressive innovation and pipeline expansion. These firms are leveraging advanced platforms for biologic synthesis, formulation, and delivery. Strategic collaborations and licensing agreements are enabling faster market entry and broader geographic reach. Biopharma players are also investing in biosimilar portfolios to capture post-patent opportunities. Their agility and focus on niche therapies position them well for sustained growth. As demand for personalized medicine increases, biopharma companies are leading the charge in biologics development.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising healthcare expenditure and expanding patient populations. Countries like China, India, and South Korea are investing heavily in biologics infrastructure and regulatory modernization. Local manufacturers are scaling up production to meet domestic and export demand. Government initiatives are promoting biosimilar adoption to reduce treatment costs. Clinical trial activity is surging, with Asia Pacific emerging as a hub for biologics research. The region's demographic and economic dynamics make it a key growth engine for the industry.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, furled by technological leadership and robust biopharma investment. The U.S. and Canada are advancing biologics innovation through academic-industry partnerships and federal funding. Regulatory agencies are streamlining approval pathways for biosimilars, encouraging market competition. Adoption of precision medicine and biologic therapies is accelerating across therapeutic areas. Digital health integration and AI-driven drug development are enhancing efficiency and outcomes.

Key players in the market

Some of the key players profiled in the Biologics & Biosimilars Market include Amgen, Sanofi, Pfizer, Eli Lilly, Novartis, Viatris, Biocon Biologics, AbbVie, Samsung Bioepis, Teva Pharmaceuticals, Celltrion, Fresenius Kabi, Roche, Boehringer Ingelheim, and Merck KGaA.

Key Developments:

In September 2025, Novartis AG has reached an agreement to purchase the New York-based firm, Tourmaline Bio Inc., in a deal valued at a staggering $1.4 billion. This move is aimed at reducing systemic inflammation, which is termed a major driver of cardiovascular disease. Novartis has been on the lookout for deals that would amplify its sales beyond 2025.

In August 2025, Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. This acquisition strengthens Sanofi's early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer's disease. In addition, the acquisition of Vigil's preclinical pipeline will further strengthen Sanofi's research in various neurodegenerative diseases.

Product Types Covered:

  • Biologics
  • Biosimilars

Therapeutic Areas Covered:

  • Oncology
  • Ophthalmology
  • Autoimmune Disorders
  • Cardiovascular
  • Endocrinology
  • Infectious Diseases
  • Hematology
  • Wound Healing & Regenerative Care

Manufacturing Sources Covered:

  • Mammalian Cell Culture
  • Yeast Expression Systems
  • Bacterial Cell Culture
  • Transgenic Models

Distribution Channels Covered:

  • Hospital Pharmacies
  • Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Hospitals
  • Diagnostic Labs
  • Research Institutes
  • Biopharma Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biologics & Biosimilars Market, By Product Type

  • 5.1 Introduction
  • 5.2 Biologics
    • 5.2.1 Monoclonal Antibodies
    • 5.2.2 Recombinant Proteins
    • 5.2.3 Hormones
    • 5.2.4 Vaccines
    • 5.2.5 Cytokines & Interferons
    • 5.2.6 Fusion Proteins
  • 5.3 Biosimilars
    • 5.3.1 Monoclonal Antibody Biosimilars
    • 5.3.2 Low Molecular Weight Heparins
    • 5.3.3 Recombinant Hormone Biosimilars
    • 5.3.4 Immunomodulators
    • 5.3.5 Anti-inflammatory Biosimilars

6 Global Biologics & Biosimilars Market, By Therapeutic Area

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Ophthalmology
  • 6.4 Autoimmune Disorders
  • 6.5 Cardiovascular
  • 6.6 Endocrinology
  • 6.7 Infectious Diseases
  • 6.8 Hematology
  • 6.9 Wound Healing & Regenerative Care

7 Global Biologics & Biosimilars Market, By Manufacturing Source

  • 7.1 Introduction
  • 7.2 Mammalian Cell Culture
  • 7.3 Yeast Expression Systems
  • 7.4 Bacterial Cell Culture
  • 7.5 Transgenic Models

8 Global Biologics & Biosimilars Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Specialty Clinics
  • 8.4 Retail Pharmacies
  • 8.5 Online Pharmacies

9 Global Biologics & Biosimilars Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Diagnostic Labs
  • 9.4 Research Institutes
  • 9.5 Biopharma Companies
  • 9.6 Other End Users

10 Global Biologics & Biosimilars Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Amgen
  • 12.2 Sanofi
  • 12.3 Pfizer
  • 12.4 Eli Lilly
  • 12.5 Novartis
  • 12.6 Viatris
  • 12.7 Biocon Biologics
  • 12.8 AbbVie
  • 12.9 Samsung Bioepis
  • 12.10 Teva Pharmaceuticals
  • 12.11 Celltrion
  • 12.12 Fresenius Kabi
  • 12.13 Roche
  • 12.14 Boehringer Ingelheim
  • 12.15 Merck KGaA

List of Tables

  • Table 1 Global Biologics & Biosimilars Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Biologics & Biosimilars Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Biologics & Biosimilars Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 4 Global Biologics & Biosimilars Market Outlook, By Monoclonal Antibodies (2024-2032) ($MN)
  • Table 5 Global Biologics & Biosimilars Market Outlook, By Recombinant Proteins (2024-2032) ($MN)
  • Table 6 Global Biologics & Biosimilars Market Outlook, By Hormones (2024-2032) ($MN)
  • Table 7 Global Biologics & Biosimilars Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 8 Global Biologics & Biosimilars Market Outlook, By Cytokines & Interferons (2024-2032) ($MN)
  • Table 9 Global Biologics & Biosimilars Market Outlook, By Fusion Proteins (2024-2032) ($MN)
  • Table 10 Global Biologics & Biosimilars Market Outlook, By Biosimilars (2024-2032) ($MN)
  • Table 11 Global Biologics & Biosimilars Market Outlook, By Monoclonal Antibody Biosimilars (2024-2032) ($MN)
  • Table 12 Global Biologics & Biosimilars Market Outlook, By Low Molecular Weight Heparins (2024-2032) ($MN)
  • Table 13 Global Biologics & Biosimilars Market Outlook, By Recombinant Hormone Biosimilars (2024-2032) ($MN)
  • Table 14 Global Biologics & Biosimilars Market Outlook, By Immunomodulators (2024-2032) ($MN)
  • Table 15 Global Biologics & Biosimilars Market Outlook, By Anti-inflammatory Biosimilars (2024-2032) ($MN)
  • Table 16 Global Biologics & Biosimilars Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 17 Global Biologics & Biosimilars Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 18 Global Biologics & Biosimilars Market Outlook, By Ophthalmology (2024-2032) ($MN)
  • Table 19 Global Biologics & Biosimilars Market Outlook, By Autoimmune Disorders (2024-2032) ($MN)
  • Table 20 Global Biologics & Biosimilars Market Outlook, By Cardiovascular (2024-2032) ($MN)
  • Table 21 Global Biologics & Biosimilars Market Outlook, By Endocrinology (2024-2032) ($MN)
  • Table 22 Global Biologics & Biosimilars Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 23 Global Biologics & Biosimilars Market Outlook, By Hematology (2024-2032) ($MN)
  • Table 24 Global Biologics & Biosimilars Market Outlook, By Wound Healing & Regenerative Care (2024-2032) ($MN)
  • Table 25 Global Biologics & Biosimilars Market Outlook, By Manufacturing Source (2024-2032) ($MN)
  • Table 26 Global Biologics & Biosimilars Market Outlook, By Mammalian Cell Culture (2024-2032) ($MN)
  • Table 27 Global Biologics & Biosimilars Market Outlook, By Yeast Expression Systems (2024-2032) ($MN)
  • Table 28 Global Biologics & Biosimilars Market Outlook, By Bacterial Cell Culture (2024-2032) ($MN)
  • Table 29 Global Biologics & Biosimilars Market Outlook, By Transgenic Models (2024-2032) ($MN)
  • Table 30 Global Biologics & Biosimilars Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 31 Global Biologics & Biosimilars Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 32 Global Biologics & Biosimilars Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 33 Global Biologics & Biosimilars Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 34 Global Biologics & Biosimilars Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 35 Global Biologics & Biosimilars Market Outlook, By End User (2024-2032) ($MN)
  • Table 36 Global Biologics & Biosimilars Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 37 Global Biologics & Biosimilars Market Outlook, By Diagnostic Labs (2024-2032) ($MN)
  • Table 38 Global Biologics & Biosimilars Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 39 Global Biologics & Biosimilars Market Outlook, By Biopharma Companies (2024-2032) ($MN)
  • Table 40 Global Biologics & Biosimilars Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.